ERNA - Company ID 0000748592
Eterna Therapeutics Inc. trades as ERNA. This page tracks Eterna Therapeutics Inc. through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Over the last 10 fiscal years Eterna Therapeutics Inc.'s revenue declined from $26.05M to $582.00K, a compound annual decline rate of 31.6%. Net profit margin compressed from -13.1% to -7652.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Annual report to shareholders | ARS | 2026-05-11 |
| Proxy materials | DEFA14A | 2026-05-11 |
The largest companies sharing Eterna Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Eterna Therapeutics Inc. reported a net loss of $14.08M.